E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028245 |
E.1.2 | Term | Multiple sclerosis |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate the safety and tolerability of oral cladribine (cladribine tablets)when added on to Rebif. Evaluate the efficacy of oral cladribine (cladribine tablets) when added on to Rebif compared to placebo when added on to Rebif in MS subjects with active disease |
|
E.2.2 | Secondary objectives of the trial |
Assess the efficacy in MS subjects with active disease of 2 cladribine tablet dose levels as an add-on to a fixed dose of Rebif (44 mcg tiw) compared to placebo as an add-on to a fixed dose of Rebif on: - lesion activity (as measured by MRI) - qualifying relapse rate - progression of disability |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. be male or female 18-55 years of age (inclusive) 2. weight between 40-120 kg inclusive 3. have definite MS as confirmed by the revised McDonald criteria (Polman et al 2005) and have relapsing forms of MS, such as relapsing remitting or secondary progressive type of disease with superimposed relapses forms (See Appendix I) 4. have experienced at leaset one relapse while receiving Rebif for at least 48 weeks prior to Screening 5. be clinically stable (other than an MS relapse) during the 28 days preceding Screening 6. have an EDSS from 1.0-5.5 inclusive (see appendi x d) 7. have not received more than one DMD other than Rebif during MS treatment history 8. have no prior exposure to immunosuppressive or cytotoxic agents 9. if female must either: a) be post menopausal or surgically sterilized or b) use a hjormonal contraceptive, intra-uterine device, dikaphragm with spermicide, or condom with spermicide, for the duration of the study and c) be neither pregnant nor breast-feeding nor attempting to conceive 10. if male must be willing to use contraception to avoid pregnancies 11. be willing and able to comply with study procedures for the duration of the study 12. have not met any of the exclusion criteria outlined in this protocol; 13. voluntarily provide written informed consent,including, for USAS, subject authroization ujnder Health Insurance Portability and Accountability Act (HIPAA), prior to any study related procedure that i not part of normal medical care, and with the understanding that the subject may withdraw consend at any time without prejudice to their future medical care |
|
E.4 | Principal exclusion criteria |
1. have primary progressive MS or secondary progressive MS without relapse forms; 2. have prior or current malignancy; 3. have a history of chronic or clinically significant hematologic abnormalities; 4. have platelet, absolute neutrophil or absolute lymphocyte counts below the lower limit of normal range or significant leukopenia (white blood cell count < 0.5 times the lower limit of normal of the central laboratory) withing 28 days prior to Study Day 1; 5. prior use of cladribine, mitoxantrone, campath-1h, cyclophosphamide, azathioprine, methotrexate, natalizumab, lymphoid irradiation, bone marrow transplantation or myelosuppressive/cytotoxic therapy; 6. use of cytokine or anti-cytokine therapy, intravenous immunoglobulin (IVIC) or plasmapheresis within 3 months prior to Study Day 1; 7. treatment with oral or systemic corticosteroids or adrenocorticotropic hormone within 28 days prior to Study Day 1; 8. subjects requires chronic or monthly pulse corticosteroids during the study; 9. use of any investigational drug or experimental procedure within 6 months prior to Study Day 1; 10. Subject has inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phsphatase 2.5 times the upper limit of the normal values; 11. subejct suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol; 12. have compromised immune function (eg HIV+) or ongoing infection; 13. have an allergy or hypersensitivity to gadolinium, to cladribine or any of its excipients, or Rebif or any of its excipient(s) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary safety endpoints will consist of safety and tolerability parameters measured over a period of 96 weeks |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |